Ultragenyx Bone Drug Stumbles In Phase 3, But Key Catalysts Remain

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares plunged 42% on Monday after the company and partner Mereo BioPharma Group plc (NASDAQ:MREO) disclosed disappointing late-stage data for their rare bone disease program.Mereo BioPharma Group plc and Ultragenyx revealed results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta (OI).The companies said that neither study achieved statistical significance against the primary endpoints of reduction in annualized clinical ...